1.2 OMIM# of the disease 194190.
1.3 Name of the analysed genes or DNA/chromosome segments 4p16.3.
OMIM# of the gene(s)
WHSC1 602952. LETM1 604407.
Mutational spectrum
Not applicable.
Analytical methods
Analytical validation
1.8 Estimated frequency of the disease (incidence at birth ('birth prevalence') or population prevalence) 1:50 000 births with a 2:1 female/male ratio. 1. 9 If applicable, prevalence in the ethnic group of investigated person Not applicable.
Diagnostic setting
Comment:
TEST CHARACTERISTICS

Analytical sensitivity (proportion of positive tests if the genotype is present)
The technology utilized for testing should be designed to detect deletion of the critical region for WHS, which includes at least portions of the LETM1 and WHSC1 genes. Therefore, either fluorescence in situ hybridization (FISH) with a probe covering this region or genomic microarray with coverage of this region should yield greater than 99% clinical sensitivity. Standard chromosome studies may not identify microdeletions of this region and would be predicated to have only a 50-60% clinical and analytical sensitivity. Also, as unbalanced translocations are frequently identified in this syndrome, genomic microarray or FISH with the subtelomeric probes should be considered to identify any concurrent duplications with the 4p deletion.
As the phenotype and genotype are interrelated for the diagnosis, then the analytical and clinical sensitivity and specificity should all be greater than 99% if the appropriate testing technology is utilized. If the test result is negative (please describe): Not applicable.
Which options in view of lifestyle and prevention does a person at-risk have if no genetic test has been done (please describe)?
Genetic risk assessment in family members of a diseased person
(To be answered if in 1.10 'C' was marked) Risk to family members depends on the mechanism of origin of the deletion. If the deletion is a simple deletion and the parents are phenotypically normal, they are very unlikely to carry a deletion. If the deletion is part of an unbalanced translocation, then there is a significant risk (greater than 50%) that either parent would carry a balanced version of the translocation.
Does the result of a genetic test resolve the genetic situation in that family?
Yes, as it will likely determine the aetiology of the disease and the recurrence risk.
Can a genetic test in the index patient save genetic or other tests in family members?
It will likely result in more genetic testing within other family members if an unbalanced translocation is identified. Larger deletions can be associated with the risk of major malformations and a more severe phenotype.
Management (please describe)
Physical, neurological and functional evaluations (cognitive, language, and motor development and social skills) are mandatory. Proper waking/sleeping video-EEG-polygraphic studies in infancy and childhood to detect type of seizures (particularly atypical absences that may be clinically missed in such children) are highly recommended. Evaluation for feeding problems and gastroesophageal reflux as needed.
Search for skeletal anomalies, with referral for orthopaedic and physical therapy evaluation, is essential. Heart examination, ophthalmology consultation; otolaryngological evaluation and audiological screening should be performed in each individual at diagnosis, even in the absence of overt anomalies. Renal function testing and renal ultrasonography are mandatory, to detect structural renal anomalies and/or vesicoureteral reflux. Planning for transition to adulthood should begin in adolescence.
Prenatal diagnosis
(To be answered if in 1.10 'D' was marked) Prenatal testing is available to families in which one parent is known to be a carrier of a chromosome rearrangement. 
